Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander J Thompson

Showing results (121-130 of 175) with videos related to

Pageof 18
Sort By:
Hepatology (Baltimore, Md.)|May 20, 2024
Effectiveness and safety of glecaprevir/pibrentasvir for 8 weeks in the treatment of patients with acute hepatitis C: A single-arm retrospective studyStanislas Pol, Alexander J Thompson, Michelle Collins, et al.
Gastroenterology|June 16, 2010
Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reductionAlexander J Thompson, Jacques Fellay, Keyur Patel, et al.
Nature|August 18, 2009
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearanceDongliang Ge, Jacques Fellay, Alexander J Thompson, et al.
Journal of Hepatology|July 31, 2023
First-in-human randomized study of RNAi therapeutic RG6346 for chronic hepatitis B virus infectionEdward J Gane, Won Kim, Tien Huey Lim, et al.
Open Forum Infectious Diseases|August 11, 2022
Care Navigation Increases Initiation of Hepatitis C Treatment After Release From Prison in a Prospective Randomized Controlled Trial: The C-LINK StudyTimothy Papaluca, Anne Craigie, Lucy McDonald, et al.
Epidemiology and Infection|March 4, 2022
Real-world monitoring progress towards the elimination of hepatitis C virus in Australia using sentinel surveillance of primary care clinics; an ecological study of hepatitis C virus antibody tests from 2009 to 2019 - CORRIGENDUMAnna Lee Wilkinson, Alisa Pedrana, Michael W Traeger, et al.
Epidemiology and Infection|March 7, 2022
Real-world monitoring progress towards the elimination of hepatitis C virus in Australia using sentinel surveillance of primary care clinics; an ecological study of hepatitis C virus antibody tests from 2009 to 2019Anna Lee Wilkinson, Alisa Pedrana, Michael W Traeger, et al.
BMC Public Health|October 16, 2021
Assessing the feasibility, acceptability and impacts of an education program on hepatitis B testing uptake among ethnic Chinese in Australia: results of a randomised controlled pilot studyYinzong Xiao, Jack Wallace, Marvad Ahad, et al.
Frontiers in Immunology|February 29, 2024
Injecting drug use and hepatitis C virus infection independently increase biomarkers of inflammatory disease risk which are incompletely restored by curative direct-acting antiviral therapyAnna C Hearps, Nikil Vootukuru, Salimeh Ebrahimnezhaddarzi, et al.
Hepatology (Baltimore, Md.)|October 6, 2015
Novel population-based study finding higher than reported hepatocellular carcinoma incidence suggests an updated approach is neededThai P Hong, Paul Gow, Michael Fink, et al.
Pageof 18

Showing results (121-130 of 175) with videos related to

Sort By:
Pageof 18
Hepatology (Baltimore, Md.)|May 20, 2024
Effectiveness and safety of glecaprevir/pibrentasvir for 8 weeks in the treatment of patients with acute hepatitis C: A single-arm retrospective studyStanislas Pol, Alexander J Thompson, Michelle Collins, et al.
Gastroenterology|June 16, 2010
Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reductionAlexander J Thompson, Jacques Fellay, Keyur Patel, et al.
Nature|August 18, 2009
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearanceDongliang Ge, Jacques Fellay, Alexander J Thompson, et al.
Journal of Hepatology|July 31, 2023
First-in-human randomized study of RNAi therapeutic RG6346 for chronic hepatitis B virus infectionEdward J Gane, Won Kim, Tien Huey Lim, et al.
Open Forum Infectious Diseases|August 11, 2022
Care Navigation Increases Initiation of Hepatitis C Treatment After Release From Prison in a Prospective Randomized Controlled Trial: The C-LINK StudyTimothy Papaluca, Anne Craigie, Lucy McDonald, et al.
Epidemiology and Infection|March 4, 2022
Real-world monitoring progress towards the elimination of hepatitis C virus in Australia using sentinel surveillance of primary care clinics; an ecological study of hepatitis C virus antibody tests from 2009 to 2019 - CORRIGENDUMAnna Lee Wilkinson, Alisa Pedrana, Michael W Traeger, et al.
Epidemiology and Infection|March 7, 2022
Real-world monitoring progress towards the elimination of hepatitis C virus in Australia using sentinel surveillance of primary care clinics; an ecological study of hepatitis C virus antibody tests from 2009 to 2019Anna Lee Wilkinson, Alisa Pedrana, Michael W Traeger, et al.
BMC Public Health|October 16, 2021
Assessing the feasibility, acceptability and impacts of an education program on hepatitis B testing uptake among ethnic Chinese in Australia: results of a randomised controlled pilot studyYinzong Xiao, Jack Wallace, Marvad Ahad, et al.
Frontiers in Immunology|February 29, 2024
Injecting drug use and hepatitis C virus infection independently increase biomarkers of inflammatory disease risk which are incompletely restored by curative direct-acting antiviral therapyAnna C Hearps, Nikil Vootukuru, Salimeh Ebrahimnezhaddarzi, et al.
Hepatology (Baltimore, Md.)|October 6, 2015
Novel population-based study finding higher than reported hepatocellular carcinoma incidence suggests an updated approach is neededThai P Hong, Paul Gow, Michael Fink, et al.
Pageof 18